Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Mar 18;48(6):794–796. doi: 10.1007/s00134-022-06681-6

Correction to: Survival benefit of extracorporeal membrane oxygenation in severe COVID-19: a multi-centre-matched cohort study

Stephen Whebell 1,6,, Joe Zhang 2,3, Rebecca Lewis 1, Michael Berry 2, Stephane Ledot 4, Andrew Retter 1, Luigi Camporota 1,5
PMCID: PMC8932462  PMID: 35304616

Correction to: Intensive Care Med 10.1007/s00134-022-06645-w

Unfortunately, the last three lines of Table 1 are incorrect. Please find the correct Table 1 below. The authors apologize for the mistake.

Table 1.

Characteristics, decision and outcomes of COVID-19 patients referred for ECMO

All referrals
(n = 1383)
Included for matching
(n = 933)
‘Perceived futility’
(n = 430)
p value
Demographics
Age 53 [45, 60] 51 [43, 58] 58 [52, 63] < 0.001
Male sex 941 (69) 641 (68.7) 300 (69.8) 0.74
Body mass index (kg/m2) 31.01 [27.02, 35.46] 31.35 [27.34, 35.64] 29.88 [26.31, 34.64] 0.002
Clinical Frailty Scale 2 [2, 2] 2 [2, 2] 2 [2, 2] < 0.001
Immunocompromised 82 (6) 40 (4.3) 42 (9.8) < 0.001
Pre-referral admission characteristics
Hospital duration prior to IMV (days) 5 [2, 8] 4.5 [2, 7.92] 6.52 [3, 9.38] < 0.001
IMV durationa (days) 3.15 [1, 6] 3 [1, 6] 4 [2, 9] < 0.001
Cardiac arrest 43 (3.2) 24 (2.6) 19 (4.4) 0.1
Therapeutic interventions
Non-invasive ventilationb prior to IMV 921 (67.6) 612 (65.6) 309 (71.9) 0.025
Corticosteroids 910 (66.8) 606 (65) 304 (70.7) 0.042
Interleukin-6 inhibitor 117 (8.6) 77 (8.3) 40 (9.3) 0.59
Neuromuscular blockade 1178 (86.4) 803 (86.1) 375 (87.2) 0.626
Prone position trial 1054 (77.3) 712 (76.3) 342 (79.5) 0.211
Inhaled nitric oxide use 168 (12.3) 98 (10.5) 70 (16.3) 0.003
Chest drain(s) for pneumothorax 83 (6.1) 55 (5.9) 28 (6.5) 0.749
Renal replacement therapy 135 (9.9) 63 (6.8) 72 (16.7) < 0.001
Noradrenaline dose (mcg/kg) 0.04 [0, 0.12] 0.03 [0, 0.1] 0.06 [0.01, 0.19] < 0.001
Anticoagulation < 0.001
 Contraindicated 11 (0.8) 7 (0.8) 4 (0.9)
 Prophylactic 883 (64.8) 647 (69.3) 236 (54.9)
 Therapeutic 469 (34.4) 279 (29.9) 190 (44.2)
Respiratory parameters at time of referral
P/F ratio (mmHg) 78.33 [64.7, 97.78] 80 [67.28, 100.5] 73.93 [61.5, 91.67] < 0.001
Static compliance (ml/cmH2O) 28.87 [20.89, 35.71] 30 [22, 37] 26.4 [19.44, 33.72] < 0.001
Vt/PBW (mL/kg) 6.7 [5.98, 7.87] 6.74 [6.06, 7.99] 6.55 [5.78, 7.61] 0.001
Driving pressure (cmH2O) 16 [13, 20] 15.7 [13, 19] 17 [14, 22] < 0.001
Plateau pressure (cmH2O) 29 [25, 31] 29 [25, 31] 29 [25, 32] 0.065
Positive end expiratory pressure (cmH2O) 12 [10, 14] 12 [10, 14] 12 [10, 14] 0.218
Minute ventilation (L/min) 9.84 [8, 11.52] 9.88 [8.04, 11.5] 9.65 [7.92, 11.63] 0.715
Arterial blood gas parameters at time of referral
pH 7.31 [7.24, 7.38] 7.32 [7.25, 7.39] 7.29 [7.20, 7.36] < 0.001
pCO2 (mmHg) 59.62 [50.25, 71.03] 58.12 [49.2, 68.55] 63.9 [53.25, 77.25] < 0.001
Bicarbonate (mmol/L) 27.02 [24, 31.45] 26.98 [24.08, 30.75] 27.6 [24, 32.6] 0.066
Base excess (mmol/L) 3.73 [1.8, 7.8] 3.6 [1.8, 7.4] 4.05 [1.8, 8.4] 0.219
Lactate (mmol/L) 1.3 [1, 1.8] 1.3 [1, 1.7] 1.4 [1, 1.8] 0.111
Laboratory parameters at time of referral
Haemoglobin (g/L) 113.55 [98, 126] 115 [101, 127] 108.5 [92, 124] < 0.001
White cell count (10ˆ9/L) 12.04 [9.31, 15.55] 11.86 [9.2, 15] 12.91 [9.8, 16.88] 0.001
Platelets (10ˆ9/L) 272.1 [229, 319.91] 278.17 [235, 325] 263.78 [218.14, 307.27] < 0.001
Creatinine (μmol/L) 73 [56, 99.63] 71 [55, 93] 79 [59.25, 117.5] < 0.001
C reactive protein (mg/L) 165.63 [76.5, 270.1] 170 [80, 274] 148.47 [68, 260] 0.1
Severity and risk scores
RESP score 4 [2.13, 5] 5 [3, 5] 3 [1, 4] < 0.001
SOFA score 5.9 [4, 8] 5 [4, 7] 7 [4, 8] < 0.001
Referral outcomes
Meets NHS criteria 608 (46.8) 463 (52.7) 145 (34.5) < 0.001
Perceived futility 430 (31.5) 0 (0) 430 (100) < 0.001
Treated with ECMO 243 (17.8) 243 (26) 0 (0) < 0.001
Died 717 (52.6) 403 (43.2) 314 (73) < 0.001

Values are expressed as median value [95% CI] or as n (%); p values for comparison statistics computed for ‘perceived futility’ vs other referral decision only

IMV invasive mechanical ventilation, P/F ratio partial pressure of arterial oxygen to fraction of inspired oxygen ratio, Vt tidal volume, PBW predicted body weight, RESP respiratory ECMO survival prediction, SOFA sequential organ failure assessment, NHS national health service

aIMV duration includes all days of IMV, regardless of intensity

bNIV use does not include high flow oxygen therapy

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Intensive Care Medicine are provided here courtesy of Nature Publishing Group

RESOURCES